Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Georges Coukos"'
Autor:
Solange Peters, Urania Dafni, Panagiota Zygoura, Sanjay Popat, Mary O'Brien, Rolf A Stahel, Alessandra Curioni-Fontecedro, Georges Coukos, Amy Roy, Riyaz Shah, Krisztian Homicsko, James Spicer, Stephen P Finn, David Gilligan, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Anthony Pope, Patricia Fisher, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression has value in this context i
Externí odkaz:
https://doaj.org/article/6dd7fca327104b5ea4d8c47266ef755b
Autor:
Martin F Bachmann, Said Dermime, Daniel E Speiser, Monique Vogel, Georges Coukos, Varghese Philipose Inchakalody, Mona O Mohsen, Justine Michaux, HuiSong Pak, Brian J Stevenson, Simone de Brot, Michal Bassani-Sternberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/214a03bc5acf409c9a81b744a3de7f23
Autor:
Pedro J Romero, Daniel E Speiser, Camilla Jandus, Alexandre Harari, Julien Schmidt, Philippe Guillaume, Amélie Cachot, Georg Alexander Rockinger, Margaux Saillard, Georges Coukos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background With immunotherapy gaining increasing approval for treatment of different tumor types, scientists rely on cutting edge methods for the monitoring of immune responses and biomarker development in patients. Due to the lack of tools to effici
Externí odkaz:
https://doaj.org/article/1366cc5a9df54d7090d02b3118ab2737
Autor:
Khalil Zaman, Z. Tsourti, Apostolos Sarivalasis, K. Vervita, J. Chenal, Georges Coukos, Lana E. Kandalaft, Urania Dafni, Klara Balint, S. Martín-Lluesma
Publikováno v:
European Journal of Cancer. 142:63-82
Background Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far. Design A systematic review and meta-analysis was conducted to evaluate vaccines’ efficacy on breast cancer (BC) and o
Autor:
Olivier Michielin, Camillo Ribi, Gerasimos P. Sykiotis, Georges Coukos, Filipe Martins, Michel H. Maillard, François Spertini, Montserrat Fraga, Solange Peters, Michel Obeid, Thierry Kuntzer, John A. Thompson
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2019, 20, pp.e54-e64. ⟨10.1016/S1470-2045(18)30828-3⟩
Lancet Oncology, Elsevier, 2019, 20, pp.e54-e64. ⟨10.1016/S1470-2045(18)30828-3⟩
Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxici
Autor:
Michel A. Cuendet, M. Caikovski, Hasna Bouchaab, Alexandre Wicky, Georges Coukos, Krisztian Homicsko, Roberto Gatta, Giorgio Valabrega, Julie Delyon, N.N. Mederos Alfonso, Eleonora Ghisoni, Sylvain Pradervand, Massimo Aglietta, Martina Imbimbo, Sofiya Latifyan, Erica Tavazzi, Solange Peters, Michel Obeid, Laura Marandino, Berna C. Özdemir, Olivier Michielin, Camille L. Gerard, M. Di Maio, B. Gautron Moura, Stefan Zimmermann
Publikováno v:
Ghisoni, E; Wicky, A; Bouchaab, H; Imbimbo, M; Delyon, J; Gautron Moura, B; Gérard, C L; Latifyan, S; Özdemir, B.C.; Caikovski, M; Pradervand, S; Tavazzi, E; Gatta, R; Marandino, L; Valabrega, G; Aglietta, M; Obeid, M; Homicsko, K; Mederos Alfonso, N N; Zimmermann, S; ... (2021). Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European journal of cancer, 149, pp. 153-164. Elsevier 10.1016/j.ejca.2021.03.010
BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration of irAEs in the literature is often incomplete. METHODS To investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57aae14ace18ed6917545af1400698eb
http://hdl.handle.net/2318/1787202
http://hdl.handle.net/2318/1787202
Autor:
Anita Wolfer, Apostolos Sarivalasis, Anneke M. Westermann, A. Casado Herraez, Judith R. Kroep, R. Le Scodan, B. Lucas, M. Auvray-Kuentz, Georges Coukos, Fernanda G. Herrera, Denarda Dangaj, Lana E. Kandalaft, Petronella B. Ottevanger, Maureen Vanlancker, Corneel Coens, M. Romeo Marin, Ana Montes, Susana Banerjee
Publikováno v:
Annals of Oncology. 32:S1308
Autor:
Thierry Kuntzer, Olivier Michielin, Latifyan Sofiya, Keyvan Shabafrouz, Faiza Lamine, Camillo Ribi, Anne Cairoli, Gerasimos P. Sykiotis, Montserrat Fraga, Yan Guex-Crosier, Michel H. Maillard, François Spertini, Solange Peters, Michel Obeid, Georges Coukos, John A. Thompson, Filipe Martins
Publikováno v:
Nature reviews. Clinical oncology. 16(9)
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer the
Autor:
Annette T. Byrne, Robert Clarke, Alejandro Piris-Giménez, Alejandra Bruna, Steven de Jong, Jos Jonkers, Leo S. Price, Ales Krenek, Simone P. Niclou, Carlos Caldas, Sergio Roman-Roman, Livio Trusolino, Michaela Th. Mayrhofer, Olivier Elemento, Mohamed Bentires-Alj, Eleonora Leucci, Enzo Medico, Gunhild Mari Mælandsmo, Alberto Villanueva, Terrence F. Meehan, Andrew V. Biankin, Giorgio Inghirami, Emilie Vinolo, Pier Giuseppe Pelicci, Luca Vezzadini, Manuel Hidalgo, Georges Coukos
Publikováno v:
Cancer Research. 78:985-985
Counteracting high attrition rates in anticancer drug development and providing optimal therapeutic management of cancer patients require preclinical models that properly recapitulate the complexity and diversity of human tumours. Patient-derived can
Autor:
Annibale Volpe, Cesare Battaglia, Antonio Bartolotti, Felice Petraglia, Georges Coukos, Alberto Segre, Carmine Nappi, Andrea R. Genazzani
Publikováno v:
Scopus-Elsevier
This study was designed to determine the presence of and possible changes in plasma and amniotic fluid immunoreactive neuropeptide-Y (irNPY) levels in pregnant women during gestation and at parturition. We studied 127 healthy pregnant and 12 nonpregn